Dr. Lauren C. Costantini is a dynamic leader with over 20 years of experience driving products from research
through commercialization. Her insights into “the art and science of building a
life science company” allow her to lead companies and non-profits at various stages
of development, fine-tuning their business plans and company strategies. Dr. Costantini has led
preclinical development, early and pivotal clinical trials, manufacturing, and
regulatory affairs for drugs, devices, medical foods, and supplements, and
plays a key role in obtaining investor funding and corporate
patent activities, and due diligence. She has an extensive network of
national and international key opinion leader and business development partners. A recognized leader in the area of central
nervous system therapeutics, she presents at numerous scientific, investor
and partnering conferences.
to founding her own firm, Dr. Costantini was Vice President at Sierra Neuropharmaceuticals focusing on new treatments for
epilepsy, and Vice President of Clinical Development at Accera where she was
instrumental in the successful commercialization of an Alzheimer’s product. Dr.
Costantini directed Product Development at Titan Pharmaceuticals, developing
novel treatments for several indications across drug delivery, gene therapy and
cell therapy platforms.
to industry, she investigated mechanisms and treatments for neurodegenerative diseases while on faculty at Harvard Medical School. Her PhD is in Biomedical
Dr. Costantini serves on several boards for
companies, journals and grant foundations including the Michael J. Fox
Foundation for Parkinson’s Research, and Cool Girls Science and Art Club which helps elementary school girls develop their passion for
science and engineering.
She is an active advisor in several business and technology advisory groups,
and enjoys teaching courses on product
translation to investigators interested in commercializing their bioscience discoveries.
Dr. Costantini was named ‘Business Advisor of the Year’ in
2011 by University of Colorado Technology Transfer, and has served ‘on the Hill’
to connect neurotechnology to policymakers.